Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YF476 in Type II Gastric Carcinoids with ZES
NCT02454075Phase 2Terminated
- Sponsor
- Trio Medicines Ltd
- Start
- Apr 2011
- Primary completion
- Jun 2012
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of netazepide in Zollinger–Ellison syndrome (ZES), type 2 gastric neuroendocrine tumor, sponsored by Trio Medicines Ltd. Started Apr 2011; status: terminated.
02
Drugs
netazepide
03
Conditions
Zollinger–Ellison syndrome (ZES)type 2 gastric neuroendocrine tumor
Beyond the preview
Go deeper on NCT02454075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454075.